Product Name | VU0467154 |
Description |
M4 Receptor Agonist |
Purity | >98% (HPLC) |
CAS No. | 1451993-15-9 |
Molecular Formula | C17H15F3N4O3S2 |
Molecular Weight | 444.45 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Blue Ice or 4ºC |
Product Type | Inhibitor |
Solubility | Soluble in DMSO |
Source | Synthetic |
Appearance | Tan Solid |
SMILES | O=S(C1=CC=C(C=C1)CNC(C2=C(N)C 3=C(C)C(C)=NN=C3S2)=O)(C(F)(F)F)= O |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | VU0467154 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-184) |
Alternative Names | 5-amino-3,4-dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno[2,3-c]pyridazine-6-carboxamide |
Research Areas | Neurodegeneration, Neuroscience, Neurotransmitter Receptors, NMDA Receptors |
PubChem ID | PMC4324418 |
Scientific Background | VU0467154 is an allosteric activator of the M4 muscarinic acetylcholine receptor, offering a novel approach to treating psychotic symptoms in schizophrenia and other neuropsychiatric disorders. In preclinical models, it reverses stimulant-induced behavioral deficits and enhances associative learning and memory. Its ability to modulate cholinergic signaling positions it as a promising candidate for cognitive enhancement and therapeutic intervention in disorders involving impaired synaptic plasticity and neurotransmission, such as Alzheimer’s disease and schizophrenia. |
References | 1. Bubser M., et. al. (2014) ACS Clinical Neuroscience 5: 920 - 942. |
StressMarq Biosciences :
Based on validation through cited publications.